Latest / Dijital Sürmanşet - International (English)

Trial suggests AR1001 slowed decline 31% in early Alzheimer’s patients off other drugs
A phase three study conducted in 13 countries indicates that AR1001, a medication designed to widen blood vessels and enhance blood flow to the brain, reduced cognitive decline by 31% among individuals with early-stage Alzheimer’s who were not using other Alzheimer’s medications. The South Korean firm AriBio, responsible for developing the drug, reported that the results involved 604 participants. Within the broader trial group, which also included those on other Alzheimer’s therapies, the outcomes did not reach statistical significance. These findings were shared at the Clinical Trials on…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.